Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI claims largely exceed or deviate from the label's documented interactions and safety guidance. Several statements are not supported by the label (noted as absent or unsupported), while a minority of points (e.g., renal clearance, hydration guidance, and general need for monitoring) are aligned. Overall alignment is limited with meaningful omissions and multiple unsupported claims.
Category Scores
Accurate Statements
Acyclovir is primarily cleared by the kidneys.
Section_2
Staying well-hydrated reduces kidney risk during acyclovir treatment.
Section_6
The 'safe' antibiotic can depend on your kidney function (known CKD, older age, dehydration).
Section_2; Section_6
Other medications (especially other kidney-impacting drugs or blood thinners).
Section_6
If you need one of these, clinicians often adjust monitoring and dosing rather than automatically avoiding acyclovir.
Section_6
Unsupported Statements
The main interaction concerns with antibiotics are usually about kidney stress and drug levels.
Absent from label; Drug Interactions guidance is not summarized as a general statement in the label.
Penicillins (for example, amoxicillin, amoxicillin-clavulanate, nafcillin/oxacillin) do not have a known, clinically significant interaction with acyclovir.
Absent from label; absence of stated interaction is not equivalent to safety.
Cephalosporins (for example, cephalexin, cefuroxime, ceftriaxone) do not have a known, clinically significant interaction with acyclovir.
Absent from label; absence of stated interaction is not equivalent to safety.
Many macrolides (for example, azithromycin, clarithromycin, erythromycin), when dosed normally, do not have a known, clinically significant interaction with acyclovir.
Absent from label; absence of stated interaction is not equivalent to safety.
Doxycycline or minocycline do not have a known, clinically significant interaction with acyclovir.
Absent from label; absence of stated interaction is not equivalent to safety.
Clindamycin do not have a known, clinically significant interaction with acyclovir.
Absent from label; absence of stated interaction is not equivalent to safety.
Nitrofurantoin (commonly used for uncomplicated urinary infections) do not have a known, clinically significant interaction with acyclovir.
Absent from label; absence of stated interaction is not equivalent to safety.
These are frequently prescribed alongside acyclovir in routine practice because they generally do not meaningfully change acyclovir absorption or acyclovir levels.
Absent from label; requires Drug Interactions data not provided as a generalized claim.
These are frequently prescribed alongside acyclovir in routine practice.
Absent from label; not explicitly stated as a blanket practice in the label.
They generally do not meaningfully change acyclovir absorption or acyclovir levels.
Absent from label; generalized absorption/levels claim not label-supported.
The interaction risk is higher with IV acyclovir because it can more directly create kidney-load and crystal-related kidney issues in some patients, especially if hydration is poor.
Absent from label; specific IV-related nephrotoxicity/crystalluria risk with antibiotics is not described in the provided label text.
With mouth (oral) acyclovir at standard doses, interactions are usually less of a concern, but kidney health still matters.
Absent from label; not label-specific phrasing.
If you’re on IV acyclovir, it’s especially important to confirm any planned antibiotic with the prescribing team.
Absent from label; not standard labeling language.
Stop and get medical advice promptly if you develop signs of kidney trouble or serious intolerance, such as: Decreased urination, New or worsening confusion, Marked swelling, Severe rash, hives, trouble breathing, Severe diarrhea or dehydration.
Not explicitly listed as a prespecified patient directive; several items appear in adverse events but not as a consumer-facing instruction.
Decreased urination
Absent from label as a standalone directive; urinary changes are listed among adverse events, not as a stand-alone patient instruction.
New or worsening confusion
Absent from label as a standalone directive; CNS symptoms are listed but not as a consumer-facing instruction.
Marked swelling
Absent from label as a standalone directive; edema is listed among adverse events but not as this instruction.
Severe rash, hives, trouble breathing
Absent from label as a consumer directive; hypersensitivity events are listed but phrasing not identical to consumer instruction.
Severe diarrhea or dehydration
Absent from label as a consumer directive; GI events are listed but not this exact instruction.
The infection type (urinary tract vs pneumonia vs skin infection).
Absent from label; not a label-directed interaction guidance statement.
The specific antibiotic and dose.
Absent from label; specific antibiotic-dose interaction data are in Drug Interactions, not as a general claim.
Other medications (especially other kidney-impacting drugs or blood thinners).
Present in label; this item is marked as supported in the claim evaluation, so considered accurate here.
Contradictions
Important Omissions
No label-supported generalized claims that specific antibiotic classes (penicillins, cephalosporins, macrolides, doxycycline/minocycline, clindamycin, nitrofurantoin) lack clinically significant interactions are provided in the label text; the AI asserted such interactions without explicit label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Overall alignment suggests limited label-supported claims about interactions; notable risk comments focus on nephrotoxicity with nephrotoxic agents, hydration, and renal impairment, which are partially captured but not comprehensively or precisely stated by the AI claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Extensive reliance on non-labeled interaction claims and multiple unsupported/absent statements; lacks label-supported Drug Interactions details and precise guidance.
Suggested Improvement
Limit claims to label-supported interactions; remove claims of universally non-interacting antibiotic classes; cite Drug Interactions sections; include IV vs oral specifics only if supported by label; add explicit hydration and renal impairment guidance aligned with Label Sections 6 and 10; avoid consumer-facing advisories not present in the label.